Foundational guide
FOXO4-DRI Where to Buy: What a Certificate Can Settle
A vendor comparison is only as good as the documents behind it. Six things a listing claims, and which of them a laboratory report can confirm, contradict or say nothing about at all.
FOXO4-DRI where to buy resolves quickly at the level of channel: no pharmacy anywhere can dispense a compound with no marketing authorisation, so research supply is the only route that exists. The harder question is which supplier, and that is a documentary question rather than a commercial one.
This guide works through what a certificate of analysis can establish about a vial, what it cannot, and where the published certificates for this product disagree with each other.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
FOXO4-DRI where to buy: four separate analytical questions
Buyers routinely collapse purity, identity, quantity and sterility into a single notion of quality. They are four different measurements, produced by different methods, and a certificate can carry any subset of them.
The distinction matters because vendors advertise the one that is cheapest to produce and quietest about the ones that are not.
| Question | Method | What it establishes | What it does not |
|---|---|---|---|
| Is it pure? | HPLC, usually UV at 214 or 220 nm | The proportion of material that is the target | How much material is present |
| Is it the right molecule? | LC-MS identity confirmation | Mass matches the theoretical value | Stereochemistry, for a D-retro-inverso peptide |
| How much is there? | Quantitative assay against a standard | Net content in milligrams | Nothing about contamination |
| Is it contaminated? | LAL endotoxin, microbial sterility | Freedom from those specific hazards | Purity or amount |
Where the two published certificates diverge
Ascension publishes two certificates for this product, produced by two laboratories covering two different batches. Read together they demonstrate the point above better than any argument could.
Kovera Labs certified batch 55-05260628 in June 2026 at 99.411% purity with net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 in January 2026 at 99.97% purity with net content of 8.30 mg. Both vials carried a 10 mg label, and both purity results were excellent.
One batch therefore came in roughly 14% above the labelled mass and the other roughly 17% below, a spread of about 37% invisible to anyone reading purity alone. Neither report is defective; they are measuring different properties and reporting both honestly.
The second divergence is scope. The June batch carries endotoxin and sterility screens; the January batch carries neither. Testing scope is a property of the batch, so a claim that this product is endotoxin tested generalises from one certificate to a product line it does not cover.
| Property | Kovera Labs | MZ Biolabs |
|---|---|---|
| Batch | 55-05260628 | 55-01260229 |
| Date | Certified 15 June 2026 | Analysed 10 January 2026 |
| Purity | 99.411% | 99.97% |
| Net content, 10 mg label | 11.41 mg | 8.30 mg |
| Endotoxin screen | Pass | Not performed |
| Sterility screen | No growth | Not performed |
| Effective cost per mg at $67.00 | About $5.87 | About $8.07 |
The D-retro-inverso identity problem
One analytical subtlety is specific to this compound and worth stating, because it limits what an identity check can prove.
FOXO4-DRI is built from D-amino acids assembled in reversed sequence. That construction gives it the same atomic composition, and therefore the same mass, as a peptide made of the corresponding L-amino acids in forward order. Mass spectrometry confirms composition; it does not distinguish stereochemistry.
So an LC-MS identity confirmation on this molecule is genuine evidence and incomplete evidence at the same time. Establishing that the material is the D-retro-inverso form rather than an L-form counterpart requires chiral analysis, which is not part of a standard certificate and is not published for this product by either laboratory.
What none of it establishes
Documentation quality and clinical evidence are unrelated axes, and a well-documented compound with no trials remains a compound with no trials.
FOXO4-DRI has never been administered to a human being in a registered study. ClinicalTrials.gov lists no interventional trial of this peptide. Every efficacy result comes from mice, rats or cultured cells, beginning with the 2017 work reporting restored fitness, fur density and renal function in aged animals.
Senolysis is also not uniformly beneficial. A 2023 report found that eliminating senescent cells could promote the development and progression of pulmonary hypertension, which is a finding a purchase decision should account for rather than a caveat to append.
Frequently asked questions
- Where can you buy FOXO4-DRI?
- From research-peptide suppliers, sold as laboratory material. No pharmacy or clinic route exists, because the compound has no marketing authorisation in any market.
- What should a certificate contain?
- At minimum a lot number matching your vial, a named laboratory, purity by HPLC and identity by mass spectrometry. Net content and contamination screening are additional and less commonly published.
- Does a purity figure tell me how much peptide I have?
- No. Purity is the proportion of present material that is the target molecule; net content is how much material is present. The two published batches assayed 11.41 mg and 8.30 mg while both testing above 99% pure.
- Can mass spectrometry confirm this is the D-retro-inverso form?
- Not on its own. A D-retro-inverso peptide has the same mass as its L-form counterpart, so mass confirms composition but not stereochemistry. Chiral analysis would be required and is not published here.
Limitations of the evidence
This guide assesses documentation, not efficacy. It cannot establish that FOXO4-DRI does anything useful in a human being: no registered interventional trial of this peptide in humans exists, so there is no clinical evidence, no human pharmacokinetics and no safety profile to weigh against any purchase decision.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Circulation · Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation · 2023PMID 36515093Preclinical